Chip Ganassi Racing Teams announced today that the Verizon IndyCar Series No. 83 Chevrolet driven by Charlie Kimball will be, Novo Nordisk’s once-daily, long-acting basal insulin medication for diabetics.
It continues the partnership Kimball, diagnosed with Type 1 diabetes in 2007, has maintained with Novo Nordisk for the eighth consecutive year. Kimball, 31, is in his sixth Verizon IndyCar Series season, all with the Ganassi team, following two years racing in Indy Lights Presented by Cooper Tires.
A passionate diabetes advocate, Kimball is the face of Novo Nordisk’s award-winning Race with Insulin campaign, which aims to raise awareness and educate the public about diabetes management.
“The new look of this car represents something very personal to me,” said Kimball, whose lone Verizon IndyCar Series win came in 2013 at Mid-Ohio Sports Car Course. “Just as there have been advancements in racing, there have been advancements in the management of diabetes. The new look of my 2016 car represents another strong link between this program and the diabetes community,” said Kimball. “I am excited about the new design, not only because of the new look, but also because it represents the next phase in my effort to educate others.”
The car’s livery features a new black and green color scheme and carries the logo of Tresiba, which was approved by the U.S. Food and Drug Administration in September 2015.
“We love the new look of Charlie’s car and are thrilled to continue our partnership with Charlie and Chip Ganassi Racing,” said Camille Lee, senior vice president, diabetes and obesity marketing, Novo Nordisk Inc. “It has been rewarding to see Charlie inspire and educate others affected by diabetes. We are looking forward to a great season with Charlie and the No. 83 Tresiba Chevrolet, and are extremely excited about the future of the Race with Insulin campaign.”
